Review Decision - October 2009
Review of NICE Technology Appraisal Guidance No 110: Rituximab for the treatment of follicular lymphoma
The Institute was proposing that it is appropriate to update the guidance.
During consultation, the majority of comments received by the Institute agreed with the proposal put forward. After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal. We will therefore update the guidance, to include the extension to the license (covering a wider range of chemotherapy regimens).
The review will be planned into the appraisal work programme at the earliest availability and inform you of the dates in due course.
This page was last updated: 30 December 2010